Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection

Rohan Merani; Mark W Johnson; Colin A McCannel; Harry W Flynn Jr; Ingrid U Scott; Alex P Hunyor

doi:10.1177/24741264221116487

Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection

J Vitreoretin Dis. 2022 Sep 8;6(6):443-451. doi: 10.1177/24741264221116487. eCollection 2022 Nov-Dec.

Authors

Rohan Merani^{1

2

3}, Mark W Johnson⁴, Colin A McCannel⁵, Harry W Flynn Jr⁶, Ingrid U Scott⁷, Alex P Hunyor²

Affiliations

¹ Concord Repatriation General Hospital, Sydney, NSW, Australia.
² Save Sight Institute, Specialty of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
³ Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW Australia.
⁴ Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
⁵ UCLA Stein Eye Institute; Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
⁶ Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USA.
⁷ Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Philadelphia, PA, USA.

Abstract

Although infectious endophthalmitis after intravitreal antivascular endothelial growth factor injections is rare, it is the most feared and potentially devastating complication of this procedure. There is no high-level evidence to provide definitive guidance on the management of endophthalmitis occurring after intravitreal injection (IVI). This clinical practice update reviews the published literature regarding post-IVI endophthalmitis and highlights areas in which further research is needed to better guide its management.

Keywords: endophthalmitis; intravitreal injection; vascular endothelial growth factor.

Publication types

Review